Interferon beta-responsive inclusion body myositis in a hepatitis C virus carrier.
Yakushiji
Y
Y
The Division of Neurology, Department of Internal Medicine, Saga University School of Medicine, Saga, Japan. yakushij@hsp.ncvc.go.jp
Satoh
J
J
Yukitake
M
M
Yamaguchi
K
K
Nakamura
I
I
Nishino
I
I
Kuroda
Y
Y
D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000097:blood / Q000821:virology; D018450:Disease Progression; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D018908:Muscle Weakness / Q000209:etiology; D018482:Muscle, Skeletal / Q000473:pathology / Q000821:virology; D018979:Myositis, Inclusion Body / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000821:virology; D012367:RNA, Viral / Q000032:analysis / Q000097:blood; D019562:Viral Load; D014766:Viremia / Q000150:complications
D000998:Antiviral Agents; D012367:RNA, Viral; D016899:Interferon-beta